The World Health Organization in its 2019 research survey has stated that in the last decade due to needle stick injury approximately 2 million healthcare professionals experienced percutaneous exposure to infectious diseases such as Hepatitis B and C virus, and HIV.
The pharmaceutical packaging market is expected to witness a CAGR of 10% during the forecast period of 2025 to 2033, driven by various compelling factors, while still facing notable challenges. The pharmaceutical packaging market is thriving due to increased pharmaceutical manufacturing, the growth of contract packaging services, and the focus on sustainable packaging. However, regulatory challenges present hurdles that need to be navigated. The shift toward glass as a preferred packaging material and the growing reliance on contract packaging services are key trends to watch.
Malarial parasites are developing resistance to anti-malarial drugs, therefore conventional treatment for malaria has proven to be less efficacious. Malaria vaccines would curb the growth of malarial cases and help save millions. Development of malaria vaccine has been one of the greatest challenges faced by research institutes and manufacturers.
Sepsis is a potentially life-threatening complication due to presence of both infection and the systemic inflammatory response; it is caused by overwhelming immune response to infection. Sepsis is treated as a medical emergency, and severe case of sepsis may lead to septic shock, in which blood pressure reduces dramatically.
Pain therapeutics are used to relieve pain either by stopping the pain signals or by altering the brain interpretation to these signals. Pain therapeutics have the ability to reduce pain intensity but do not treat the cause of the pain.
Cell cultures are an important and fundamental tool essential for the development of target based therapies such as biosimilars, biologics and personalized medicine. The current trend for developing medication is making it more patient centric thus personalized medicines are in greater demand for treating various chronic conditions and orphan indications. The development of target based therapies for the above-mentioned conditions require to be carried at a faster pace with no scope for errors during the development stages.
Whey protein ingredients are referred to as globular proteins which are extracted from whey, a liquid obtained as a derivative of cheese. Consumers are preferring whey protein ingredients due to their high protein content as compared to egg, soy and other dairy products. Whey proteins are widely consumed in the form of nutritional supplements owing to various health benefits related with them.
Diabetic foot ulcers is a type of chronic wound affecting millions of patients across the globe. Diabetic foot ulcers are thickened wounds below the ankle in a diabetic patient irrespective of its duration. On account of high prevalence of diabetes, increasing geriatric population and lack of awareness on preventive measures the global diabetic foot ulcers market shows a lucrative growth between the forecast period 2025 and 2033.
Natural alternative sweeteners, also known as sugar substitutes are chemicals which are added to some food products to make them taste sweet with presence of little or no calories. The over consumption of sugary foods leads to weight gain, resistance to insulin, type 2 diabetes and fatty liver. Therefore, in a bid to satisfy consumer’s sweet tooth without compromising with the health has led scientists and nutrition professionals to develop healthier natural alternatives to sugar.
Electronic batch record (EBR) refer to software that electronically stores and manages data for a given batch as well as the whole manufacturing process step-by-step. The software uses the existing enterprise resource planning (ERP) system to systematically produce a formal master batch record or electronic batch record. This stores all of the materials, processes and activities that went into producing a given product.
The drugs by therapeutic area market covers pharmaceutical products classified according to the diseases and medical conditions they are designed to treat. Major therapeutic areas include oncology, cardiovascular diseases, diabetes and other metabolic disorders, neurological conditions, infectious diseases, respiratory disorders, immunology, gastrointestinal diseases, dermatology, ophthalmology, women’s health and rare diseases. The category includes prescription drugs, generic medicines, biologics, biosimilars, vaccines and advanced therapies.
The wider global pharmaceutical market provides an appropriate benchmark for evaluating growth across therapeutic drug categories. One current industry estimate projects the pharmaceutical market to increase from approximately USD 1.88 trillion in 2026 to USD 3.22 trillion by 2035, representing a compound annual growth rate of 6.15%. North America held the largest regional share in 2025, while Asia-Pacific is expected to demonstrate notable growth through 2035.
Market growth is being supported by the increasing prevalence of chronic and age-related diseases. Rising cases of cancer, diabetes, cardiovascular disorders, arthritis, respiratory diseases and neurological conditions are creating sustained demand for effective treatments. Population ageing, lifestyle changes, urbanization and improved access to diagnosis are further expanding the number of patients receiving long-term therapy.
Oncology remains an important area for pharmaceutical research and commercial investment. Development activity includes targeted therapies, immune checkpoint inhibitors, antibody-drug conjugates, cell therapies and personalized cancer treatments. Diabetes and obesity drugs are also recording strong demand, supported by the wider use of GLP-1 and other metabolic treatments. Neurology research is expanding across Alzheimer’s disease, Parkinson’s disease, epilepsy and mental health conditions.
Biologic drugs and biosimilars represent major market trends. Biologics are increasingly used to treat cancer, autoimmune diseases and rare disorders, while biosimilars can improve access after reference-product patent expiry. Pharmaceutical companies are also developing gene therapies, RNA-based medicines and other advanced treatments for conditions with limited existing options.
Precision medicine is influencing drug development across multiple therapeutic areas. Biomarkers, genomic testing and companion diagnostics help identify patients who are more likely to respond to specific medicines. Artificial intelligence is also being used for target identification, clinical-trial planning and analysis of real-world treatment data.
Market expansion may be restrained by high research costs, lengthy clinical development, regulatory uncertainty and drug-pricing pressure. Patent expirations can reduce revenue for branded products, while safety concerns or unsuccessful clinical trials may delay commercial launches. Access and reimbursement remain major challenges for expensive biologics and advanced therapies.
Acute Market Reports provides therapeutic-area drug research covering product classes, disease indications, routes of administration, distribution channels, company pipelines, competitive conditions and regional opportunities. These reports help pharmaceutical companies, investors, healthcare providers and distributors evaluate treatment demand and growth prospects through 2035.